Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/48172
Título: Erythropoietin in cancer treatment: Considerations about Henke's article
Autores/as: Biete Sola, Alberto
Calvo Manuel, Felipe A.
Clavo Varas, Bernardino 
Fernández Pérez, Cristina
Porto Vázquez, Carmen
De La Torre Tomás, Alejandro
Zapatero Laborda, Almudena
Clasificación UNESCO: 32 Ciencias médicas
320101 Oncología
Palabras clave: Anemia
Erythropietin
Neoplasm
Fecha de publicación: 2005
Publicación seriada: Clinical and Translational Oncology 
Resumen: The concurrent use of erythropoietin beta (EPO)and radiotherapy in head and neck cancer patients has been reported by Henke et al (Lancet 2003;362:1255-60) to correct anemia and impair cancer control. Due to the potential impact in daily clinical practice of this information a systematic critical review of the mentioned article was performed. Authors selected 10 arguments to question the contents regarding methodological and statistical aspects of the trial, and added 14 comments of controversy in more basic scientific concepts mentioned in the text as published. The panel including epidemiologist and radiation oncologists with expertise in clinical research concluded with 5 additional remarks recommending caution in interpretation of these results in terms of changes in daily practice of anemic patients support, and advising not to use EPO at experimental doses or after reaching physiological concentrations of hemoglobin.
URI: http://hdl.handle.net/10553/48172
ISSN: 1699-048X
DOI: 10.1007/BF02716548
Fuente: Clinical and Translational Oncology[ISSN 1699-048X],v. 7, p. 332-335
Colección:Actas de congresos
Vista completa

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.